|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69133566T2
(de)
|
1990-01-12 |
2007-12-06 |
Amgen Fremont Inc. |
Bildung von xenogenen Antikörpern
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
WO1992003918A1
(en)
|
1990-08-29 |
1992-03-19 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
CA2061566C
(en)
|
1992-02-20 |
2002-07-09 |
Rudolf E. Falk |
Treatment of disease employing hyaluronic acid and nsaids
|
|
CA2061703C
(en)
|
1992-02-20 |
2002-07-02 |
Rudolf E. Falk |
Formulations containing hyaluronic acid
|
|
DE69233745D1
(de)
|
1991-12-02 |
2008-10-23 |
Cambridge Antibody Tech |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
|
CA2130762C
(en)
|
1994-08-24 |
1999-07-06 |
Eva Anne Turley |
Treatment of disease and conditions associated with macrophage infiltration
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
AU6819494A
(en)
|
1993-04-26 |
1994-11-21 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
|
CA2156924A1
(en)
|
1993-12-27 |
1995-07-06 |
Ton That Hai |
Water soluble non-immunogenic polyamide cross-linking agents
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
NZ321172A
(en)
|
1995-10-03 |
2000-02-28 |
Scripps Research Inst |
CBI analogs of CC-1065 and the duocarmycins
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1998042752A1
(en)
|
1997-03-21 |
1998-10-01 |
Brigham And Women's Hospital Inc. |
Immunotherapeutic ctla-4 binding peptides
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
EP1746107B1
(en)
|
1998-04-02 |
2014-12-17 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PT1176195E
(pt)
|
1999-04-09 |
2013-07-18 |
Kyowa Hakko Kirin Co Ltd |
Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
|
|
US20040031072A1
(en)
|
1999-05-06 |
2004-02-12 |
La Rosa Thomas J. |
Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
|
|
CN100358577C
(zh)
|
1999-05-07 |
2008-01-02 |
杰南技术公司 |
抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
|
|
US20040146516A1
(en)
|
1999-06-17 |
2004-07-29 |
Utah Ventures Ii L.P. |
Lumen-exposed molecules and methods for targeted delivery
|
|
JP4118462B2
(ja)
|
1999-07-19 |
2008-07-16 |
株式会社リコー |
携帯電子機器
|
|
EP1074563A1
(en)
|
1999-08-02 |
2001-02-07 |
F. Hoffmann-La Roche Ag |
Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
|
|
IL148021A0
(en)
|
1999-08-23 |
2002-09-12 |
Dana Farber Cancer Inst Inc |
Novel b7-4 molecules and uses therefor
|
|
WO2001014424A2
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
EP1265582A2
(en)
|
1999-09-29 |
2002-12-18 |
Human Genome Sciences, Inc. |
Colon and colon cancer associated polynucleotides and polypeptides
|
|
AU784634B2
(en)
|
1999-11-30 |
2006-05-18 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
|
WO2001046232A2
(en)
|
1999-12-23 |
2001-06-28 |
Zymogenetics, Inc. |
Soluble interleukin-20 receptor
|
|
WO2001046261A1
(en)
|
1999-12-23 |
2001-06-28 |
Zymogenetics, Inc. |
Method for treating inflammation
|
|
US20070042392A1
(en)
|
2000-02-03 |
2007-02-22 |
Nuvelo, Inc. |
Novel nucleic acids and polypeptides
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
KR20020091170A
(ko)
|
2000-03-31 |
2002-12-05 |
아이덱 파마슈티칼즈 코포레이션 |
Ｂ 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-ｃｄ２０의 조합된 사용
|
|
HUP0002003A3
(en)
|
2000-05-24 |
2003-01-28 |
Pronuk Biotechnologia Kft |
Process and reagent-kit for determining of 5'-nucleotidase activity
|
|
NO311144B1
(no)
|
2000-05-25 |
2001-10-15 |
Pedersen Viggo Wahl |
Spylemekanisme for vannklosett
|
|
AU2001273224A1
(en)
|
2000-07-07 |
2002-01-21 |
University Of North Carolina At Chapel Hill |
Isolated polynucleotides encoding human 5'-nucleotide cn-ia and cn-ib, isolated proteins encoded by the same, and methods utilizing the same
|
|
US8263741B2
(en)
|
2000-07-11 |
2012-09-11 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
|
DE60131456T2
(de)
|
2000-11-30 |
2008-07-10 |
Medarex, Inc., Milpitas |
Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
HUP0303428A2
(hu)
|
2001-03-07 |
2004-01-28 |
Merck Patent Gmbh. |
Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
|
|
WO2002092780A2
(en)
|
2001-05-17 |
2002-11-21 |
Diversa Corporation |
Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
|
|
US7087600B2
(en)
|
2001-05-31 |
2006-08-08 |
Medarex, Inc. |
Peptidyl prodrugs and linkers and stabilizers useful therefor
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
US6545530B1
(en)
|
2001-12-05 |
2003-04-08 |
Linear Technology Corporation |
Circuit and method for reducing quiescent current in a voltage reference circuit
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
EP1562972B1
(en)
|
2002-10-15 |
2010-09-08 |
Facet Biotech Corporation |
ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
|
|
ES2897506T3
(es)
|
2003-01-09 |
2022-03-01 |
Macrogenics Inc |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
|
|
WO2004079013A1
(en)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
KR101424624B1
(ko)
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
|
CA2527878A1
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
|
CN1829533A
(zh)
|
2003-05-30 |
2006-09-06 |
阿莱克申药物公司 |
包含改造恒定区的抗体和融合蛋白
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US7473531B1
(en)
|
2003-08-08 |
2009-01-06 |
Colora Corporation |
Pancreatic cancer targets and uses thereof
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
|
PL1706424T3
(pl)
|
2004-01-12 |
2010-04-30 |
Mentrik Biotech Llc |
Warianty regionu Fc
|
|
US7329353B2
(en)
|
2004-01-23 |
2008-02-12 |
Amgen Inc. |
LC/MS method of analyzing high molecular weight proteins
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
US7778814B2
(en)
|
2004-03-30 |
2010-08-17 |
Siemens Aktiengesellschaft |
Method and device for simulating an automation system
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
JP4806680B2
(ja)
|
2004-05-19 |
2011-11-02 |
メダレックス インコーポレイテッド |
自己犠牲リンカー及び薬剤複合体
|
|
TWI355389B
(en)
|
2004-07-30 |
2012-01-01 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide a
|
|
AU2005274905B2
(en)
|
2004-08-04 |
2010-12-23 |
Mentrik Biotech, Llc |
Variant Fc regions
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
SG156672A1
(en)
|
2004-10-22 |
2009-11-26 |
Amgen Inc |
Methods for refolding of recombinant antibodies
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
CA2588613C
(en)
|
2004-11-23 |
2010-09-14 |
Pip Co., Ltd. |
Built-in wall water service box
|
|
WO2006075668A1
(ja)
|
2005-01-12 |
2006-07-20 |
Kirin Beer Kabushiki Kaisha |
安定化されたヒトIgG2およびIgG3抗体
|
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
EP1896582A4
(en)
|
2005-05-09 |
2009-04-08 |
Ono Pharmaceutical Co |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
|
|
CN101212967A
(zh)
|
2005-05-10 |
2008-07-02 |
因塞特公司 |
吲哚胺2,3-双加氧酶调节剂及其用法
|
|
ES2523666T3
(es)
|
2005-05-31 |
2014-11-28 |
Board Of Regents, The University Of Texas System |
Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
NZ566982A
(en)
|
2005-09-26 |
2011-06-30 |
Medarex Inc |
Duocarmycin drug conjugates
|
|
WO2007038868A2
(en)
|
2005-10-03 |
2007-04-12 |
The University Of British Columbia |
Novel enediyne compound and uses thereof
|
|
EP1940789B1
(en)
|
2005-10-26 |
2011-11-23 |
Medarex, Inc. |
Methods and compounds for preparing cc-1065 analogs
|
|
US20080206246A1
(en)
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
PE20080316A1
(es)
|
2006-05-25 |
2008-04-10 |
Bristol Myers Squibb Co |
Compuestos de aziridinil-epotilona
|
|
AR062448A1
(es)
|
2006-05-25 |
2008-11-12 |
Endocyte Inc |
Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
|
|
DE102006027624A1
(de)
|
2006-06-13 |
2007-12-20 |
Elexxion Gmbh |
Handstück für insbesondere medizinische Laseranwendungen
|
|
EP2044123B1
(en)
|
2006-06-21 |
2013-03-13 |
Oncotherapy Science, Inc. |
Tumor-targeting monoclonal antibodies to fzd10 and uses thereof
|
|
US20150030534A1
(en)
|
2013-07-26 |
2015-01-29 |
Rutgers, The State University Of New Jersey |
Antibody cocktails for breast cancer radioimmunotherapy
|
|
EP2078732B1
(en)
*
|
2006-07-10 |
2015-09-16 |
Fujita Health University |
Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
|
|
CA2663057C
(en)
|
2006-09-19 |
2015-12-08 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
EP2609932B1
(en)
|
2006-12-01 |
2022-02-02 |
Seagen Inc. |
Variant target binding agents and uses thereof
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
AU2008218766A1
(en)
|
2007-02-21 |
2008-08-28 |
Medarex, Inc. |
Chemical linkers with single amino acids and conjugates thereof
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
US7867491B2
(en)
|
2007-05-30 |
2011-01-11 |
Genexine Co., Ltd. |
Immunoglobulin fusion proteins
|
|
EA019485B1
(ru)
|
2007-07-17 |
2014-04-30 |
Мерк Патент Гмбх |
Сконструированные гибридные антитела против альфа v интегрина
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
DE102007036200A1
(de)
|
2007-08-02 |
2009-02-05 |
Knorr-Bremse Systeme für Nutzfahrzeuge GmbH |
Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
EP4512422A3
(en)
|
2007-09-14 |
2025-05-21 |
Amgen Inc. |
Homogenous antibody populations
|
|
WO2009041613A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
抗体定常領域改変体
|
|
BRPI0817250A2
(pt)
*
|
2007-09-26 |
2014-06-17 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-receptor da il-6.
|
|
MY148637A
(en)
*
|
2007-09-28 |
2013-05-15 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican-3 antibody having improved kinetics in plasma
|
|
BRPI0816014A8
(pt)
|
2007-10-01 |
2018-06-19 |
Bristol Myers Squibb Co |
anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
|
|
EP2203180B1
(en)
*
|
2007-10-22 |
2012-11-21 |
Merck Serono S.A. |
Single ifn-beta fused to a mutated igg fc fragment
|
|
FI20070795A0
(fi)
|
2007-10-24 |
2007-10-24 |
Faron Pharmaceuticals Oy |
Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
|
|
US8975081B2
(en)
|
2007-10-24 |
2015-03-10 |
Faron Pharmaceuticals Oy |
Biomarker for monitoring development of diseases and assessing the efficacy of therapies
|
|
CN101918027A
(zh)
|
2007-11-02 |
2010-12-15 |
森托科尔奥索生物科技公司 |
半合成GLP-1肽-Fc融合构造、方法及其用途
|
|
EP2229187A2
(en)
|
2007-11-30 |
2010-09-22 |
Bristol-Myers Squibb Company |
Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
|
|
AR069747A1
(es)
|
2007-11-30 |
2010-02-17 |
Medarex Inc |
Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
|
|
EP2227233B1
(en)
|
2007-11-30 |
2013-02-13 |
Newlink Genetics |
Ido inhibitors
|
|
KR20160074019A
(ko)
|
2007-12-05 |
2016-06-27 |
추가이 세이야쿠 가부시키가이샤 |
항ｎｒ１０ 항체 및 그의 이용
|
|
WO2009079242A2
(en)
|
2007-12-05 |
2009-06-25 |
Massachusetts Institute Of Technology |
Aglycosylated immunoglobulin mutants
|
|
DK2808343T3
(da)
|
2007-12-26 |
2019-08-19 |
Xencor Inc |
Fc-varianter med ændret binding til FcRn
|
|
DK2234620T3
(en)
|
2008-01-03 |
2016-06-06 |
Université D'aix-Marseille |
Triple therapy used for treatment of an hiv-infected patient
|
|
WO2009100309A2
(en)
|
2008-02-08 |
2009-08-13 |
Medimmune, Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
CN102089325A
(zh)
|
2008-04-17 |
2011-06-08 |
埃博灵克斯股份有限公司 |
能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
|
|
EP2282773B2
(en)
|
2008-05-02 |
2025-03-05 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
US20100189727A1
(en)
|
2008-12-08 |
2010-07-29 |
Tegopharm Corporation |
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
|
|
TW202442680A
(zh)
|
2008-12-09 |
2024-11-01 |
美商建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
|
JP5843357B2
(ja)
|
2009-02-03 |
2016-01-13 |
アムニクス オペレーティング インコーポレイテッド |
延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
US9228017B2
(en)
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
US20110007023A1
(en)
|
2009-07-09 |
2011-01-13 |
Sony Ericsson Mobile Communications Ab |
Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
|
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
|
IN2012DN01920A
(cg-RX-API-DMAC7.html)
|
2009-09-03 |
2015-07-24 |
Schering Corp |
|
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
ES2601226T3
(es)
|
2009-10-28 |
2017-02-14 |
Newlink Genetics Corporation |
Derivados de imidazol como inhibidores de IDO
|
|
JO3437B1
(ar)
|
2009-10-30 |
2019-10-20 |
Esai R & D Man Co Ltd |
أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
|
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
|
KR101791430B1
(ko)
|
2009-11-30 |
2017-10-30 |
얀센 바이오테크 인코포레이티드 |
이펙터 기능이 제거된 항체 Ｆｃ 돌연변이체
|
|
CN102711449B
(zh)
|
2009-12-10 |
2015-01-07 |
瑞泽恩制药公司 |
生产重链抗体的小鼠
|
|
CN105218672A
(zh)
|
2009-12-10 |
2016-01-06 |
霍夫曼-拉罗奇有限公司 |
优先结合人csf1r胞外域4的抗体及其用途
|
|
PL3095871T3
(pl)
|
2010-02-08 |
2019-10-31 |
Regeneron Pharma |
Mysz zawierająca wspólny łańcuch lekki
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
PT3053932T
(pt)
|
2010-02-19 |
2020-10-21 |
Xencor Inc |
Novas imunoadesinas ctla4-ig
|
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
|
EP2982380B1
(en)
|
2010-03-04 |
2021-09-01 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
JP2013523098A
(ja)
|
2010-03-29 |
2013-06-17 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
EA022983B1
(ru)
|
2010-04-13 |
2016-04-29 |
Бристол-Майерс Сквибб Компани |
Белки на основе структурного домена фибронектина, связывающие pcsk9
|
|
EP2558475A1
(en)
|
2010-04-15 |
2013-02-20 |
Spirogen Sàrl |
Pyrrolobenzodiazepines used to treat proliferative diseases
|
|
CN103068405A
(zh)
|
2010-04-15 |
2013-04-24 |
西雅图基因公司 |
靶向吡咯并苯并二氮杂卓结合物
|
|
EP2561088A1
(en)
|
2010-04-22 |
2013-02-27 |
Institut Gustave Roussy |
Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
|
|
WO2011131246A1
(en)
|
2010-04-22 |
2011-10-27 |
Institut Gustave Roussy |
Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
|
|
US8828944B2
(en)
|
2010-04-22 |
2014-09-09 |
Institut Gustave Roussy |
Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
|
|
WO2012007783A1
(en)
|
2010-07-13 |
2012-01-19 |
Institut Gustave Roussy |
Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
|
|
US8865653B2
(en)
|
2010-04-22 |
2014-10-21 |
Institut Gustave Roussy |
Method of treatment for immunogenic treatment resistant cancer
|
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
|
CN112480256A
(zh)
|
2010-05-04 |
2021-03-12 |
戊瑞治疗有限公司 |
结合csf1r的抗体
|
|
ME02902B
(me)
|
2010-06-22 |
2018-04-20 |
Regeneron Pharma |
Transgeni miševi sa modifikovanim lokusom endogenog lambda imunoglobulina
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012012736A2
(en)
|
2010-07-23 |
2012-01-26 |
The Ohio State University |
Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway
|
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
MX345300B
(es)
|
2010-07-30 |
2017-01-24 |
Novartis Ag * |
Moléculas andamio de fibronectina y bibliotecas de las mismas.
|
|
WO2012031320A1
(en)
|
2010-09-06 |
2012-03-15 |
Peter Maccallum Cancer Institute |
Cancer diagnostic
|
|
DK2614082T3
(en)
|
2010-09-09 |
2018-11-26 |
Pfizer |
4-1BB BINDING MOLECULES
|
|
JP6006640B2
(ja)
|
2010-10-29 |
2016-10-12 |
株式会社ペルセウスプロテオミクス |
高い内在化能力を有する抗ｃｄｈ３抗体
|
|
US20140010812A1
(en)
|
2010-12-20 |
2014-01-09 |
Rockefeller University (The) |
Modulating agonistic tnfr antibodies
|
|
RU2636029C2
(ru)
*
|
2011-02-01 |
2017-11-17 |
Генмаб А/С |
Человеческие антитела и конъюгаты антитело-препарат против cd74
|
|
KR20230005405A
(ko)
|
2011-02-25 |
2023-01-09 |
추가이 세이야쿠 가부시키가이샤 |
ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
|
|
SI2697257T1
(sl)
|
2011-04-13 |
2017-02-28 |
Bristol-Myers Squibb Company |
FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
|
|
NO2694640T3
(cg-RX-API-DMAC7.html)
|
2011-04-15 |
2018-03-17 |
|
|
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
|
CN103987718A
(zh)
|
2011-09-20 |
2014-08-13 |
斯皮罗根有限公司 |
作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
|
|
WO2013095738A2
(en)
|
2011-09-27 |
2013-06-27 |
Mapp Biopharmaceutical, Inc. |
Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
|
|
ES2402038B1
(es)
|
2011-10-14 |
2013-11-25 |
Josep Ramon Viola Terès |
Base para palé y palé provisto de esta
|
|
WO2013086448A2
(en)
|
2011-12-07 |
2013-06-13 |
Amgen Inc |
IgG2 DISULFIDE ISOFORM SEPARATION
|
|
CA2853889A1
(en)
|
2011-12-15 |
2013-06-20 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
EA031715B1
(ru)
|
2011-12-19 |
2019-02-28 |
Дзе Рокфеллер Юниверсити |
ПРОТИВОВОСПАЛИТЕЛЬНЫЙ НЕСИАЛИРОВАННЫЙ ПОЛИПЕПТИД МОДИФИЦИРОВАННОГО Fc-УЧАСТКА hIgG1, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ
|
|
JP2015506372A
(ja)
|
2012-01-27 |
2015-03-02 |
グリックニック インコーポレイテッド |
ＩｇＧ２ヒンジドメインを含む融合タンパク質
|
|
WO2013119716A1
(en)
|
2012-02-06 |
2013-08-15 |
Genentech, Inc. |
Compositions and methods for using csf1r inhibitors
|
|
MX350539B
(es)
|
2012-02-13 |
2017-09-08 |
Bristol Myers Squibb Co |
Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
JP2015517490A
(ja)
|
2012-05-11 |
2015-06-22 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
EA037351B8
(ru)
|
2012-05-15 |
2021-04-29 |
Бристол-Майерс Сквибб Компани |
Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
|
|
US9943574B2
(en)
|
2012-06-27 |
2018-04-17 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
BR112015004426A2
(pt)
|
2012-08-31 |
2018-08-28 |
Five Prime Therapeutics, Inc. |
método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória
|
|
SG11201501741YA
(en)
|
2012-09-13 |
2015-04-29 |
Bristol Myers Squibb Co |
Fibronectin based scaffold domain proteins that bind to myostatin
|
|
BR112015019432A2
(pt)
|
2013-02-14 |
2017-08-22 |
Bristol Myers Squibb Co |
Compostos de tubulisina, métodos de produção e uso
|
|
WO2014153424A1
(en)
|
2013-03-19 |
2014-09-25 |
La Jolla Institute For Allergy And Immunology |
Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
|
|
KR102049991B1
(ko)
|
2013-03-28 |
2019-12-02 |
삼성전자주식회사 |
항 c-Met/항 Her2 이중 특이 항체
|
|
CN103278634B
(zh)
|
2013-05-16 |
2015-01-07 |
中国科学院近代物理研究所 |
Cd73作为肾透明细胞癌干细胞表面标志物的应用
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
US10081681B2
(en)
|
2013-09-20 |
2018-09-25 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
KR102056963B1
(ko)
|
2013-12-30 |
2019-12-17 |
에피맙 바이오테라퓨틱스 인코포레이티드 |
Fabs-인-탠덤 면역글로불린 및 이의 용도
|
|
CN107172880B
(zh)
|
2014-03-24 |
2021-09-28 |
癌症研究技术有限公司 |
含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
|
|
US10654884B2
(en)
|
2014-04-25 |
2020-05-19 |
Boehringer Ingelheim International Gmbh |
Purine derivatives as CD73 inhibitors for the treatment of cancer
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
EP3204417B1
(en)
|
2014-10-10 |
2020-07-22 |
Innate Pharma |
Cd73 blockade
|
|
JP6755866B2
(ja)
|
2014-11-10 |
2020-09-16 |
メディミューン リミテッド |
Ｃｄ７３特異的結合分子及びその使用
|
|
JP6847037B2
(ja)
|
2014-11-11 |
2021-03-24 |
メディミューン リミテッド |
抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
|
|
WO2016081746A2
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
ES2807182T3
(es)
|
2014-11-21 |
2021-02-22 |
Bristol Myers Squibb Co |
Anticuerpos frente a CD73 y sus usos
|
|
BR112018010172A2
(pt)
|
2015-11-19 |
2018-11-21 |
Bristol Myers Squibb Co |
anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
|
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
ES2923143T3
(es)
|
2017-05-25 |
2022-09-23 |
Bristol Myers Squibb Co |
Anticuerpos monoclonales antagonistas contra CD40 y sus usos
|
|
JP2020521458A
(ja)
|
2017-05-25 |
2020-07-27 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物
|
|
EP3630833A1
(en)
|
2017-05-25 |
2020-04-08 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
KR20200142542A
(ko)
|
2018-04-12 |
2020-12-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
|
|
EP3887397A1
(en)
|
2018-11-28 |
2021-10-06 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|